Dr. Peter Marks Discusses Next Steps After Advisory Committee Recommendation - 6/15/2023

we did hear the recommendation for uh an updated composition uh to an xbv containing uh monovalent vaccine we did hear the preference for an xbb 1.5 um uh vaccine and we'll make a decision quickly regarding the specific composition to recommend to manufacturers for uh the the uh the coming uh season uh I think our our decision obviously will incorporate uh what we've heard today and I

I don't think it will come as any surprise based on the discussion today um uh and then we anticipate that the manufacturers will be moving forward uh with uh manufacturing and then obtaining data and filings needed to inform our ultimate FDA actions um uh in order to have vaccines evaluated um uh with our safety and effect goodness standards for availability in the September time frame